Immunosequencing Hstcrb_V4b (Ultradeep) Sequencing Services Tender, USA - 100444813

Procurement Summary

Country : USA

Summary : Immunosequencing Hstcrb_V4b (Ultradeep) Sequencing Services

Deadline : 30 Apr 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 100444813

Document Ref. No. : NOI-NIAID-24-2146191-Ver2

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Purchaser : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Contracting Office Address : BETHESDA, MD 20892
Primary Point of Contact : Dana Monroe
dana.monroe@nih.gov
Phone Number 4063759814

USA
Email :dana.monroe@nih.gov

Tender Details

Description

PRE-SOLICITATION NOTICE ** NOTICE OF INTENT

NOI-NIAID-24-2146191.Ver 2

NAICS - 541380, Testing Laboratories



This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Adaptive Biotechnologies for immunosequencing hsTCRB_v4b (UltraDeep) sequencing services; QTY 53 samples.

This requirement is for the analysis of the immune response to COVID-19 vaccination and outcomes in individuals with and without immune deficiencies and dysregulations by the NIAID Laboratory of Clinical Immunology and Microbiology (LCIM). The goal of this is study is to research the crucial role of T cells in the induction of effector and memory responses to viral infections, however limited information is available on T cell-mediated responses to SARS-CoV-2 in immunocompetent and immunocompromised individuals. Studies have shown that an impaired adaptive immune response may contribute to worse clinical outcomes in COVID-19 patients with critical disease and hematological malignancies by studying the SARS-CoV-2 specific TRB repertoire along with TRBV and TRBJ gene usage. While multiple SARS-CoV-2 vaccines have become widely available in the US, there is still limited information available on T cell-mediated responses to post SARS-CoV-2 vaccination status in immunocompetent and immunocompromised individuals. To successfully complete this final task of 53 samples, LCIM must perform high throughput sequencing of the T cell receptor beta repertoire as previously completed. This deep sequencing was previously done by Adaptive Biotechnologies and switching vendors will greatly impact the data set, continuity values and ability to make comparisons of the immune response, thus this final requirement for 53 EA samples of immunosequencing hsTCRB_v4b service must be completed by Adaptive Biotec...
Active Contract Opportunity Notice ID NOI-NIAID-24-2146191-Ver2 Related Notice Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier NATIONAL INSTITUTES OF HEALTH Office NATIONAL INSTITUTES OF HEALTH NIAID
General Information
Contract Opportunity Type: Presolicitation (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Apr 24, 2024 03:51 pm EDT
Original Response Date: Apr 30, 2024 05:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: May 15, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
NAICS Code: 541380 - Testing Laboratories and Services

Place of Performance: Bethesda, MD 20892 USA

Documents

 Tender Notice